Inventiva SA
PAR:IVA
Inventiva SA
Long-Term Debt
Inventiva SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€48.5m
|
CAGR 3-Years
77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€193m
|
CAGR 3-Years
23%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Innate Pharma SA
PAR:IPH
|
Long-Term Debt
€63.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
33%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€59.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
28%
|
|
|
DBV Technologies SA
PAR:DBV
|
Long-Term Debt
$6.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Long-Term Debt
€78.7m
|
CAGR 3-Years
84%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Long-Term Debt?
Long-Term Debt
48.5m
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Long-Term Debt amounts to 48.5m EUR.
What is Inventiva SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
77%
Over the last year, the Long-Term Debt growth was 51%. The average annual Long-Term Debt growth rates for Inventiva SA have been 77% over the past three years .
You don't have any saved screeners yet